Hormonal
Gastric bypass surgery (GBP) improves glucose metabolism and reduces obesity risk partly by altering gut microbiota composition and increasing the secretion of gut hormones (GLP-1, PYY), often before significant weight loss occurs.
Gastric bypass surgery reverses type 2 diabetes and improves metabolic health rapidly, often before significant weight loss. This is driven by anatomical changes that increase beneficial gut hormones (GLP-1, PYY) and alter gut bacteria. It is a highly effective intervention for severe obesity and diabetes.
weight loss following bariatric surgery in morbidly obese patients with type 2 diabetes leads to a rapid reversal of the pathophysiology and subsequent resolution of diabetes mellitus... this glycaemic improvement actually occurs before weight loss... Several studies have reported an increase in postprandial plasma levels of PYY and/or GLP-1 as early as 2 days after bypass.
Why this rating
Strong clinical evidence from human studies showing rapid metabolic improvement post-surgery, supported by mechanistic animal/human data on hormones and microbiota.
Source
The environment within: how gut microbiota may influence metabolism and body composition
A. Vrieze et al. · Diabetologia · 2010
DOI 10.1007/s00125-010-1662-7
More from this paper
- Gut microbiota composition influences body weight and metabolic health by increasing energy harvest from diet and modulating host fat storage pathways, with obese individuals harboring microbiota that extract more energy from the same diet than lean individuals.Moderate
- Gut microbiota composition influences metabolic health through the production of short-chain fatty acids (SCFAs) like butyrate, which have anti-inflammatory properties and improve insulin sensitivity, and through the modulation of gut hormones like GLP-1 and PYY.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →